(NASDAQ: PSTV) Plus Therapeutics's forecast annual revenue growth rate of 106.37% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.53%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.5%.
Plus Therapeutics's revenue in 2026 is $5,213,000.On average, 7 Wall Street analysts forecast PSTV's revenue for 2026 to be $1,362,798,745, with the lowest PSTV revenue forecast at $672,478,736, and the highest PSTV revenue forecast at $2,810,000,433. On average, 6 Wall Street analysts forecast PSTV's revenue for 2027 to be $4,098,689,277, with the lowest PSTV revenue forecast at $2,554,046,792, and the highest PSTV revenue forecast at $5,043,590,521.
In 2028, PSTV is forecast to generate $8,113,833,363 in revenue, with the lowest revenue forecast at $6,753,264,777 and the highest revenue forecast at $9,907,052,810.